QUOTED. 8 April 2021. Harry Keenan.
Executive Summary
In the three months since Brexit, UK medtech stakeholders have seen the beginning of new regulations, foreign trade plans being put into place, and perhaps new perceptions of medtech’s value. See what Harry Keenan, DCC Vital group managing director, said about it here.
“We should be aligned as [much as] we possibly can, to allow the free flow of goods.” – Harry Keenan, group managing director, DCC Vital
- Find out more: UK Regulatory System Progress And New MedTech Directorate Unveiled At Industry Meeting
Click here for a free trial of Medtech Insight